# US 2025/0205359 A1 · Ferrisilicate composition and method for treating insulin deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205359 A1
- Document ID: US20250205359A1
- Status: Published application
- Kind: A1
- Application number: 19/075,871
- Filed: 2025-03-11
- Published: 2025-06-26
- Earliest claimed: 2022-09-09
- Assignees: Imam Abdulrahman Bin Faisal University
- Applicants: Imam Abdulrahman Bin Faisal University
- Inventors: B. Rabindran JERMY; Vijaya RAVINAYAGAM; Mohammed SALAHUDDIN
- Web page: https://patentgrep.com/patent/US20250205359A1

## CPC

- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1611: {Inorganic compounds}
- A61K 31/695: Silicon compounds
- A61K 33/26: Iron; Compounds thereof
- A61K 38/28: Insulins
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of delivering insulin, including: orally administering to a subject a composition containing a ferrisilicate material, polyethylene glycol, and insulin. The insulin at least partially penetrates pores of the ferrisilicate material to form a ferrisilicate insulin composite and the polyethylene glycol, at least partially enfolds the ferrisilicate insulin composite to form the composition. The composition has an insulin release rate of 10-50% after 100-500 hours following oral administration.

## Claims

### Claim 1

A method of administering insulin, comprising:
orally administering to a subject a composition comprising,
a ferrisilicate material having one or more pores, the one or more pores having an average pore size of from 2 nm to 5 nm;
polyethylene glycol; and
insulin;
wherein the composition is administered in the form of granules, a suspension or tablet,
wherein the insulin at least partially penetrates the pores of the ferrisilicate material to form a ferrisilicate insulin composite,
wherein the polyethylene glycol, at least partially enfolds the ferrisilicate insulin composite, and
wherein the composition has a cumulative insulin release of about 40% after 500 hours following oral administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ferrisilicate material has an atomic ratio of silicon to iron of 10-300 to 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ferrisilicate material has cubic shaped pores.

### Claim 4 (depends on 1)

The method of claim 1, wherein the insulin is amorphous.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ferrisilicate insulin composite has a surface area of 300-350 square meter per gram (m2/g).

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition has a pore volume of 0.1-0.5 cubic centimeter per gram (cm3/g).

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein at least a portion of the polyethylene glycol is hydrogen-bonded to the insulin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ferrisilicate insulin composite has 5-90 weight percent (wt %) insulin based on the total weight of the ferrisilicate insulin composite.

### Claim 10 (depends on 1)

The method of claim 1, wherein the ferrisilicate insulin composite has 60-80 wt % insulin based on the total weight of the ferrisilicate insulin composite.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein 1-100 milligrams (mg) of the composition per kg body weight of the subject is orally administered.

### Claim 14 (depends on 1)

The method of claim 1, wherein the blood glucose level of the subject is decreased following oral administration of the composition.

### Claim 15 (depends on 14)

The method of claim 14, wherein the blood glucose level is decreased by 5-40% after 1-3 hours following oral administration of the composition.

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition is administered daily.

### Claim 17 (depends on 16)

The method of claim 16, wherein the blood glucose level of the subject is decreased by 20-50% after 28 days.

### Claim 18 (depends on 14)

The method of claim 14, wherein the blood glucose level is decreased by a greater amount than a same method administering only the insulin.

### Claim 19

(canceled)
